SMARCB1 and neoplasm: The antagonism between SWI/SNF and PRC2 led some workers to hypothesize that relief of this antagonism in INI1-negative cancers might lead to an over-dependence on PRC2 activity and thereby make these tumours particularly vulnerable to inhibitors of EZH2 [29].